NWBO didn't file with the FDA -- no company would pass on filing in the U.S. unless FDA told them they didn't have sufficient clinical evidence. NWBO has very limited revenue potential in a small personalized oncology market like the UK. A winning personalized oncology treatment, Gilead's Yescarta CAR-T, only had 318 patients paid for by NICE's CDF Charity in three years!!! All at very discounted pricing.
Market Data 
Markets 
AI
